Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies. J of Skin [Internet]. 2023 Nov. 13 [cited 2025 May 17];7(6):s294. Available from: https://skin.dermsquared.com/skin/article/view/2377